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Abstract
African Americans are disproportionately affected by type 2 diabetes (T2DM) yet few studies have examined T2DM using
genome-wide association approaches in this ethnicity. The aim of this study was to identify genes associated with T2DM in the
African American population. We performed a Genome Wide Association Study (GWAS) using the Affymetrix 6.0 array in 965
African-American cases with T2DM and end-stage renal disease (T2DM-ESRD) and 1029 population-based controls. The most
significant SNPs (n=550 independentloci) weregenotyped ina replication cohort and 122 SNPs (n=98 independentloci) were
further tested through genotyping three additional validation cohorts followed by meta-analysis in all five cohorts totaling
3,132 cases and 3,317 controls. Twelve SNPs had evidence of association in the GWAS (P,0.0071), were directionally consistent
in the Replication cohort and were associated with T2DM in subjects without nephropathy (P,0.05). Meta-analysis in all cases
and controls revealed a single SNP reaching genome-wide significance (P,2.5610
28). SNP rs7560163 (P=7.0 610
29,O R( 9 5 %
CI)=0.75 (0.67–0.84)) is located intergenically between RND3 and RBM43. Four additional loci (rs7542900, rs4659485, rs2722769
and rs7107217) were associated with T2DM (P,0.05) and reached more nominal levels of significance (P,2.5610
25)i nt h e
overall analysis and may represent novel loci that contribute to T2DM. We have identified novel T2DM-susceptibility variants in
the African-American population. Notably, T2DM risk was associated with the major allele and implies an interesting genetic
architecture in this population. These results suggest that multiple loci underlie T2DM susceptibility in the African-American
population and that these loci are distinct from those identified in other ethnic populations.
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Introduction
African Americans have a disproportionately high risk for
developing type 2 diabetes (T2DM) with an estimated prevalence
twice that observed for their European-American counterparts [1].
In addition to socioeconomic and behavioral risk factors, genetic
factors are likely contributors to the disproportionate risk ob-
served in this population. Genome-Wide Association Studies
(GWAS) have been used extensively with great success to identify
common genetic variants associated with T2DM in primarily
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29202European-derived populations [2,3,4]. Until recently, comparable
studies have been difficult to perform in African Americans due to
the greater complexity of their African-derived genome compound-
ed by recent admixture of European-derived genes. With the
development of high density SNP arrays that give reasonable
coverage of the African-American genome and methods to account
for admixture in this population, it has become possible to perform
informative GWAS in the African-American population. The aim
of this study was to identify loci that contribute to T2DM by GWAS
and replication in multiple African-American samples.
Results
Clinical characteristics of the study samples
The clinical characteristics of the study samples used in the
GWAS, Replication and Validation phases are shown in Table 1.
The GWAS and Replication populations were similar. In both
groups, the age at enrollment for the T2DM-ESRD subjects was
older than for the control groups. However, the mean age at
enrollment for the control groups in the GWAS and Replication
phases was older than the mean age of T2DM diagnosis in the
T2DM-ESRD and T2DM subjects. Notably, the use of population-
based controls has not precluded the identification of bona fide
associations in other efforts (e.g., [2]). All of the case groups with
T2DM (T2DM-ESRD and T2DM) had a higher proportion of
females; possibly reflecting the increased prevalence of T2DM
among African-American women [5], participation bias and/or
survival. On average, all of the groups were overweight or obese at
the time of enrollment. Among case subjects, those with T2DM-
ESRD had the lowest average body mass index (BMI; 29.7 kg/m
2,
Table 1), and the T2DM subjects without nephropathy (T2DM)
had the highest average BMI (33.5 kg/m
2, Table 1).
GWAS
After the application of SNP and sample quality control metrics,
832,357 directly-genotyped, autosomal SNPs were analyzed in 965
African-American T2DM-ESRD case subjects and 1,029 African-
American controls lacking T2DM and ESRD. Given the modest
increase of the inflation factor with inclusion of related individuals
(1.04 versus 1.06) cryptic first degree relatives were retained in
the analysis. A summary of the association results is shown in
Figure 1 and Figure S1. The top hit was rs5750250 located on
chromosome 22 in the MYH9 (non-muscle myosin heavy chain 9)
gene (P-value=3.0610
27, Figure 1). This gene has been previously
associated with non-diabetic and diabetic forms of ESRD [6,7,8,9].
In total, there were 126 SNPs with P-values,1.0610
24 (Figure 1).
In addition, we also evaluated previously identified T2DM index
variants and their corresponding CEU LD blocks for association
with T2DM in the African-American population (Table S1).
Among the 37 T2DM index variants [3,10,11,12,13,14,15,16,17,18,
19,20,21,22,23,24,25,26,27] identified to date from candidate gene
studies, large scale association studies and GWAS, 35 were directly-
genotyped or imputed. Among these, 20 SNPs showed consistency
with the Caucasian-defined risk allele, although most were non-
significant. Only rs11634397 and rs7903146 were nominally
associated (P=0.016 and 4.9E-05, respectively) although the
direction of effect was inconsistent for rs11634397 with previous
studies (OR=0.86 with respect to the Caucasian risk allele G).
Notably, additional signals of association were observed in CEU LD
blocks containing the index SNP. After correction for multiple
comparisons, only SNP rs4506565 in TCF7L2 remained significant
(Bonferroni-corrected P=0.027; n=18 SNPs (10 effective tests)
contained in the CEU LD block and genotyped in the African-
American GWAS). The flow of the study through the GWAS,
Replication and Validation phases is outlined in Table 2.
Replication and GWAS + Replication Analysis of T2DM-
ESRD cases and controls lacking both T2DM and ESRD
In an effort to replicate the GWAS results, the most significant
712 SNPs (n=550 independent loci) were successfully genotyped in
an additional sample of 709 African-American T2DM-ESRD cases
and 690 African-American controls lacking both T2DM and ESRD
(Table 2). In this replication analysis, 70 of the 712 SNPs (9.8%)
showed nominal evidence of replication: a P-value,0.05 under an
additive genetic model with association in the same direction. Al-
though no SNP reached genome-wide significance (P-value#
2.5610
28), P-values ranged from 7.6610
24 to 6.5610
27 (GWAS
+ Replication). The top hit from the GWAS, rs5750250, did not
reach nominal significance in the replication cohort (P-value=0.054).
Validation of T2DM loci
A total of 122 SNPs were genotyped in three independent
cohorts comprising a total of 1,458 African-American T2DM
cases and 1,598 controls lacking both T2DM and ESRD
(Table 2). These included 56 of the 70 SNPs with evidence of
Table 1. Clinical Characteristics of Study Samples.
GWAS Replication Validation
T2DM Case-Control IRAS IRASFS
T2DM-ESRD Control T2DM-ESRD Control T2DM Control T2DM Control T2DM Control
n 965 1029 709 690 1246 927 115 164 97 507
Female (%) 61.2% 57.3% 55.7% 51.3% 64.0% 58.0% 53.9% 61.0% 70.1% 58.0%
Age at Enrollment (years) 61.6610.5 49.0611.9 60.2610.4 48.5612.8 57.2611.7 46.6613.1 56.868.0 54.568.4 53.9611.2 40.8613.5
Age at T2DM diagnosis
(years)
41.6612.4 _ 39.4612.5 _ 46.1612.6 51.1610.7 _ 51.2611.9 _
Age at ESRD diagnosis
(years)
58.0610.9 _ 56.761 0 . 9 _______
T2DM to ESRD duration
(years)
16.2610.9 _ 20.461 0 . 5 _______
BMI (kg/m
2) 29.767.0 30.067.0 29.866.9 29.467.6 33.567.6 30.067.7 32.166.0 29.365.8 34.166.8 29.266.5
Values are presented as trait mean and standard deviation.
doi:10.1371/journal.pone.0029202.t001
Type 2 Diabetes GWAS in African Americans
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in the combined analysis (Table S2). These samples allowed
differentiation between association with T2DM or T2DM-ESRD
while increasing power of detection for suspected T2DM loci
through meta-analysis. Meta-analysis of the five putative T2DM
SNPs in Validation samples, revealed association signals with
P-values ranging from 0.011–1.8610
26 (Table S3, Table 3). The
most significant SNP was rs7560163 (P=1.8610
26, odds ratio
(OR) (95% confidence interval (95%CI)=0.74 (0.63–0.87)) located
intergenicallybetweenRND3(Rashomologgenefamily,memberE)
and RBM43 (RNA binding motif protein 43).
Meta-analysis of all African-American study samples
The association results of all 122 SNPs successfully genotyped in
all five cohorts (GWAS, Replication, T2DM, IRAS and IRASFS)
were used in a meta-analysis to compute an overall test of
association (Table 3). This analysis combined results from cases
(T2DM-ESRD and T2DM; n=3,132) and controls (lacking both
T2DM and ESRD; n=3,317) for a sample size of 6,449 individuals.
As a result of this analysis, one SNP reached genome-wide
significance (P-value#2.5610
28; Table 3 and Figure S2). SNP
rs7560163 (P=7.0610
29, OR (95% CI)=0.75 (0.67–0.84)) is
located intergenically between RND3 and RBM43. This SNP
was tested for association with T2DM, in silico, by the Diabetes
Genetics Replication and Meta-analysis (DIAGRAM) Consort-
ium [3] however failed quality control filters and was not in-
cluded in analysis likely due to being monomorphic as seen in a
representative Caucasian population from the HapMap project
(Table S4).
Quantitative Trait Analysis
Exploration of putative T2DM variants with quantitative
glycemic traits in a subset of African-American samples (n=671
from the IRAS and IRASFS control samples, Table S5) revealed
Table 2. Study Design.
Stage
SNPs
(Independent Loci) Cases Control Admixture Adjustment
GWAS 832,357 T2DM-ESRD Cases (n=965) Population-based Controls (n=1029) Principal Component 1 (PC1)
Replication 712
(550)
T2DM-ESRD Cases (n=709) Population-based Controls (n=690) FRAPPE (70 AIMs)
GWAS + Replication 712
(550)
T2DM-ESRD Cases (n=1,674) Population-based Controls (n=1,719)
Validation 122
(98)
T2DM Cases (n=1,246) Controls (n=927) FRAPPE (76 AIMs)
122
(98)
IRAS T2DM Cases (n=115) IRAS Controls (n=164) FRAPPE (70 AIMs)
122
(98)
IRASFS T2DM Cases (n=97) IRASFS Controls (n=507) FRAPPE (70 AIMs)
Validation Meta-analysis 122
(98)
T2DM Cases (n=1,458) Controls (n=1,598)
Overall Meta-analysis
(All 5 cohorts)
122
(98)
T2DM Cases (n=3,132) Controls (n=3,317)
doi:10.1371/journal.pone.0029202.t002
Figure 1. Genome-Wide Association Study Results. Results are adjusted for admixture using PC1 as a covariate in the analysis. P-values are
shown under the additive model. The blue line at -log10(P-value)=3 represents an additive P-value=0.001 and the red line at -log10(P-value)=5
represents a P-value=1.0610
25.
doi:10.1371/journal.pone.0029202.g001
Type 2 Diabetes GWAS in African Americans
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T2DM risk. In addition, the five putative African-American
T2DM susceptibility loci were tested for association with
quantitative measures of glucose homeostasis in the European
Caucasian population, in silico, by the Meta-Analyses of Glucose
and Insulin-related traits Consortium (MAGIC; [16]). These
results did not provide further insight into the probable role these
variants may have in disease susceptibility (Table S6). The most
significantly associated SNP in African Americans, rs7560163,
failed quality controls filters and was not included in analysis likely
due to being monomorphic as seen in a representative Caucasian
population from the HapMap project (Table S4).
Exploration of eQTLs for T2DM loci
Evaluation of three of the five putative African-American
T2DM susceptibility loci for association with altered expression
levels of neighboring genes revealed no strong evidence of
association. However, SNP rs7542900 trended toward association
with CNN3 (b=0.20+/20.12, P=0.095). Lack of association
could be due to the small sample size (n=90), ethnic differences
(African vs. African American) or lack of identification of the
causal variant. SNPs rs4659485 and rs2722769 were not evaluated
as they are monomorphic in the YRI population.
Discussion
We performed a high-density genome-wide association study to
investigate the genetic determinants of T2DM in the African-
American population. Meta-analysis of five study cohorts revealed
a single SNP, rs7560163, near RND3 that contributes to T2DM in
the African-American population. It is noteworthy that this locus
and more nominally associated loci are distinct from those
implicated in previous GWAS of T2DM in primarily European-
derived populations. These results are consistent with our prior
observations [28,29] that ‘‘European’’ genes appear to make only
modest contributions to inter-individual risk of T2DM in the
African-American population.
Although the associations observed reside intergenically, several
neighboring genes could be implicated and have characteristics
relevant to the pathophysiology of T2DM. The nearest annotated
gene to SNP rs7560163, the only SNP identified to reach stringent
levels of genome-wide significance in the Overall analysis
(P=7.0 610
29, OR=0.75 (0.67–0.84); Table 3), is RND3.T h i s
gene encodes the Rho family GTPase 3 which is ubiquitously
expressed and has been implicated as a regulator of actin cytoskeleton
organization in response to extracellular growth factors [30,31].
Additional SNPs that reached nominal significance in the Validation
samples but failed to reach stringent criteria for genome-wide
significance in the Overall analysis included SNP rs7542900 located
upstream of coagulation factor III precursor (F3). Higher expression
levels of F3 have been measured in monocytes from patients with
T2DM [32] although this association could be related to unmeasured
vascular complications [33,34]. In addition, SNP rs4659485 is
located intergenically between the cardiac muscle ryanodine receptor
(RYR2) and 5-methyltetrahydrofolate-homocysteine (MTR) genes
however, a biological relationship with T2DM is not clearly evident.
SNP rs2722769 resides ,64 kb upstream of UDP-N-acetyl-alpha-D-
galactosamine polypeptide (GALNTL4).GALNTL4 is a member of the
large subfamily of glycosyltransferases and although little is known
about its biological function, GALNTL2 has been implicated in
cholesterol metabolism in a large GWAS meta-analysis [35]. Among
other top hits, rs7107217 is located downstream of BarH-like
homeobox 2 (BARX2), a transcription factor expressed in smooth and
skeletal muscle and involved in muscle differentiation [36,37,38].
Exploration of putative T2DM variants with quantitative
glycemic traits in a subset of the samples (n=671, Table S5)
revealed limited insight into the biological mechanism associated
with T2DM risk. Notably among the SNPs and traits examined,
only SNP rs7107217 was nominally associated with fasting insulin
(P=0.011). Exploration of these variants in European Caucasian
populations represented by the DIAGRAM Consortium [3] and
MAGIC [16] revealed only nominal evidence of association with
T2DM (rs7107217 P=0.086, located intergenically between
BARX2 and NFRKB; Table S4) and did not provide further insight
into the probable role of these variants in disease susceptibility
through examination of quantitative measures of glucose homeo-
stasis (Table S6), respectively.
To put these findings into context, the association of TCF7L2
with T2DM has been widely replicated across multiple ethnicities
(reviewed in [39] including prior analysis of African-American
samples included in this study [28,40]). SNP rs7903146 has been
the most strongly associated variant within this locus with one of
the largest allelic odds ratio (OR) for a common variant, i.e. OR
,1.35 [3]. Although rs7903146 is not typed on the Affymetrix 6.0
array and given that the genomic interval is not tagged well (max
r
2=0.45), only nominal evidence of association was observed in
our African-American GWAS (P=0.0015, rs4506565; Table S1).
Direct genotyping of rs7903146 in the GWAS + Replication
(n=1,674 T2DM-ESRD cases and 1,719 controls lacking both
T2DM and ESRD) resulted in the most strongly associated signal
observed (P=2.46610
28) with an odds ratio (OR=1.33, 95%
CI=1.19–1.48). This odds ratio is in the range of other signals
which were observed (Table 3).
A notable observation common to all putative T2DM loci
(Table 3) is the association of ‘‘protection’’, i.e. and odds ratio less
than 1.0, with the minor allele. Comparison with data from the
International HapMap Consortium [41] confirms that the major
allele in all instances is more common in the representative African
samples (YRI) from Ibadan, Nigeria. This could suggest that
selection for diabetogenic traits is occurring and that the more
common, African-derived allele is deleterious in a more western-
ized environment. This is consistent with a trend we observed in
prior tests of ‘‘European’’ T2DM associated variants in African
Americans (20).
Since obesity is known to be a significant risk factor for the
development of T2DM we explored the potential influence using a
surrogate measure of adiposity, body mass index (BMI). As seen in
Table 1, BMI differs significantly in the validation cohorts
(P,0.0001). Given this significant difference, association analyses
were repeated with inclusion of BMI as a covariate in the analysis.
Adjustment for BMI did not substantially affect the strength of the
associations observed. For example, the most significant hit from
the validation analysis, rs7560163, was significantly associated
with T2DM in the Validation cohorts (n=1,149 T2DM cases and
919 controls with BMI data; P=3.59610
26) and remained
the most interesting observation after adjusting for BMI (P=
2.83610
26; data not shown). Additionally, all the case groups with
T2DM (T2DM-ESRD and T2DM) had a higher proportion of
females (Table 1); possibly reflecting the increased prevalence of
disease in women [5]. Gender stratified analyses revealed seven of
the ten most strongly associated loci were more significant in
women (P=0.0010-3.2E-07; Table S7) although nine of the loci
remained significantly associated in men (P=0.028-3.9E-06;
Table S7). Notably, the power to detect association is diminished
when the sample size is reduced (n=2648 men and 3781 women).
This study has similar limitations to other GWAS conducted in
minority populations. Although the current study has a modest
sample size for the GWAS discovery phase compared to large-scale
Type 2 Diabetes GWAS in African Americans
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(Tables S8 and S9) show that this study has greater than 80%
statistical power to detect effects for common variants (MAF=0.20)
consistent with published effect sizes (OR=1.28) for T2DM (e.g.
transcription factor 7-like 2 (TCF7L2) and potassium voltage-gated
channel, KQT-like subfamily, member 1 (KCNQ1) with ORs 1.3–
1.4; reviewed by [4]) and more modest power (,70%) to detect
effects for less common variants (MAF=0.10). The power to detect
and replicate moderate level contributions to T2DM susceptibility
should increase with meta-analysis of this GWAS data and other
GWAS currently being conducted in African-American popula-
tions. In addition this study reports results from only directly
genotyped SNPs. Effective imputation of additional SNPs would
undoubtedly improve coverage of the African-American genome.
While recent imputation methods development [42] show encour-
aging progress,rigorous empirical testing continues. A potential bias
of the current study design may be that the GWAS was conducted
in an African-American population of individuals with type 2
diabetes with nephropathy however; there is no specific reason why
this African-American population should differ substantially from
African Americans with T2DM without ESRD. For example,
TCF7L2 is strongly associated in our studies of African-American
T2DM-ESRD subjects [28,40]. In addition it should be noted that
although every precaution was taken to account for population
structure, as with any GWAS or candidate gene study, there may be
residual population substructure. The major strength of this study is
the genotyping and replication in four additional populations, thus
providing support for the evidence of association observed. In
addition, the study design which includes individuals with T2DM
and ESRD allows for the identification of ESRD loci which are
distinct from those presented herein (Table S10; [43]).
In conclusion, we have performed a GWAS for T2DM-ESRD in
an African-American population from the southeastern United
States. These results were then replicated in an additional sample
recruited under identical ascertainment criteria. As a second stage
of replication, a Validation study was carried out in three in-
dependent cohorts to confirm the association of suspected loci with
T2DM. As a result, we have identified SNP rs7560163 that reached
stringent levels of genome-wide significance and four additional loci
with more nominal evidence of association. These findings require
further replication in independent African-American populations as
well as in additional ethnicities to confirm these findings and aid in
the identification of the causal variant(s).
Materials and Methods
Ethics Statement
Recruitment and sample collection procedures were approved
by the Institutional Review Board at Wake Forest University
(GWAS, Replication, T2DM, IRAS and IRASFS samples) and
Howard University (HUFS samples). Written informed consent
was obtained from all study participants.
Subjects
Genome-Wide Association Study (GWAS) samples and
clinical characteristics. Recruitment and sample collection
procedures were approved by the Institutional Review Board at
Wake Forest University and informed consent was obtained from
all study participants. Patients with T2DM-ESRD were recruited
from dialysis facilities. T2DM was diagnosed in African Americans
who reported developing T2DM after the age of 25 and who did
not receive only insulin therapy since diagnosis. In addition, cases
had to have at least one of the following three criteria for inclu-
sion: a) T2DM diagnosed at least 5 years before initiating renal
replacement therapy, b) background or greater diabetic retinopathy
and/or c) $100 mg/dl proteinuria on urinalysis in the absence of
other causes of nephropathy (T2DM-ESRD cases). Unrelated
African-American controls without a current diagnosis of diabetes
or renal disease were recruited from the community and internal
medicine clinics (controls). All T2DM-ESRD cases and controls
lacking T2DM and ESRD were born in North Carolina, South
Carolina, Georgia, Tennessee or Virginia. DNA extraction was
performed using the PureGene system (Gentra Systems;
Minneapolis, MN).
Replication study samples and clinical charac-
teristics. African-American T2DM-ESRD cases and controls
lacking T2DM and ESRD were recruited using the same criteria
as the case and control subjects that were used in the GWAS.
Validation study samples and clinical charac-
teristics. T2DM Cases. Subjects with T2DM without evidence
of nephropathy were recruited from medical clinics, churches,
health fairs and community resources. Individuals were unrelated
and self-described African Americans. All subjects were born in
North Carolina, South Carolina, Georgia, Virginia or Tennessee.
The PureGene system (Gentra Systems; Minneapolis, MN) was
used for DNA extraction. Controls. The Howard University Family
Study (HUFS) is a population-based study of African-American
families enrolled from the Washington, D.C. metropolitan area.
Families were not ascertained based on a given phenotype. In a
second phase of recruitment, additional unrelated individuals
from the same geographic area were enrolled to facilitate a nested
case-control study design. A total of 1,976 samples remained after
data cleaning. Diagnosis of T2DM was based on the criteria
established by the American Diabetes Association Expert
Committee: a fasting plasma glucose concentration $126 mg/
dL (7.0 mmol/l) or a 2-h postload value in the oral glucose
tolerance test $200 mg/dL (11.1 mmol/l) on more than one
occasion or receiving medication for T2DM. From this sample, a
subset of 927 unrelated control individuals was used for analysis.
IRAS. The Insulin Resistance Atherosclerosis Study (IRAS) is a
multicenter population-based cohort study that recruited men and
women from 40 to 69 years of age living in four U.S. communities
from 1992 to 1993 [44]. The study recruited approximately equal
numbers of persons with normal glucose tolerance, impaired
glucose tolerance and T2DM. Diabetes was defined by self-report
or a fasting glucose measures .126 mg/dL at baseline or follow-
up visits. The IRAS protocol was approved by local institutional
review committees and all participants gave informed consent.
IRASFS. Study design, recruitment and phenotyping for the IRAS
Family Study (IRASFS) have been described [45]. Briefly, the
IRASFS is a multicenter study designed to identify the genetic
determinants of quantitative measures of glucose homeostasis.
Members of large families of self-reported African Americans
(n=581 individuals in 42 pedigrees from Los Angeles, California)
were recruited. Diabetes was defined by self-report, use of diabetes
medications or fasting glucose measures .126 mg/dL at baseline
or follow-up visits. The IRASFS protocol was approved by local
institutional review committees and all participants gave informed
consent.
Genotyping and Quality Control
GWAS. Genotyping was performed at the Center for
Inherited Disease Research (CIDR) using 1 mg of genomic DNA
(diluted in 16 TE buffer and at 50 ng/ml) on the Affymetrix
Genome-wide Human SNP array 6.0. DNA from cases and
controls were equally interleaved on 96-well master plates to
ensure technical uniformity during sample processing. To confirm
sample identity, a SNP barcode (96 SNPs) was generated prior to
Type 2 Diabetes GWAS in African Americans
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downstream released genotyping data. Genotypes were called
using Birdseed version 2; APT 1.10.0 by grouping samples by
DNA plate to determine the genotype cluster boundaries. All
autosomal SNPs (n=868,157) were included in analysis but
classified on data quality with primary inference drawn from SNPs
(n=832,357) which had less than 5% missing data, Hardy-
Weinberg P-values in cases greater than 0.0001 and in controls
greater than 0.01, no significant difference in missing data rate
between cases and controls and were polymorphic. The average
sample call rate was 99.16% for all autosomal SNPs. Forty-six
blind duplicates were included in genotyping and had a
concordance rate of 99.59%. In addition, individuals whose
gender call from X chromosome genotype data was discordant
with the gender obtained from patient interviews were excluded
from the analysis (n=1). Cryptic relatedness was estimated by
pairwise identity-by-descent (IBD) analysis implemented in the
PLINK analysis software package (http://pngu.mgh.harvard.edu/
purcell/plink/). Two duplicate samples were identified, and one
sample in each duplicate pair was removed. In addition, 104
individuals were identified as cryptic first degree relatives. We also
assessed heterozygosity by estimating the inbreeding coefficient
using PLINK. One subject had an F value .4 standard deviations;
this excess of homozygosity would suggest population substructure
and this subject was removed. Our final dataset consisted of 1994
individuals in which we performed the association analysis.
Replication. The replication sample consisted of a
population recruited under identical ascertainment criteria to
that of the GWAS. A total of 749 SNPs (including 272 SNPs
captured in 104 linkage disequilibrium (LD) blocks defined by an
r
2.0.50 at consecutive loci as assessed in 988 unrelated GWAS
control subjects; 581 independent loci) were selected for
genotyping on the Sequenom MassArray platform (Sequenom;
San Diego, CA). Case and control samples were genotyped and
analyzed together to avoid sample-dependent SNP calling bias.
SNPs were included in analysis if genotyping was greater than
90% efficient, had a Hardy-Weinberg P-value$0.001 in the
replication cohort and were polymorphic (n=712 SNPs, including
264 SNPs captured in 102 LD blocks defined by an r
2.0.50 at
consecutive loci as assessed in 988 unrelated GWAS control
subjects; 550 independent loci). Forty five blind duplicate samples
included in genotyping had a concordance rate of .99.9%.
Validation. Among the 712 SNPs genotyped during the
replication phase, 122 (including 41 SNPs captured in 17 linkage
disequilibrium (LD) blocks defined by an r
2.0.50 at consecutive
loci as assessed in 690 unrelated Replication control subjects; 98
independent loci) were genotyped using the iPLEX
TM Sequenom
MassARRAY platform (T2DM, IRAS and IRASFS) or on the
Affymetrix Genome-wide Human SNP array 6.0 (Controls) for the
validation phase. Genotyping was greater than 90% efficient and
the 50 blind duplicate samples included in genotyping had a
concordance rate of 100%.
Analysis
GWAS. To address the effect of admixture in this African-
American dataset we performed a Principal Components Analysis
(PCA) which utilized all high quality data from the GWAS
excluding regions of high LD and inversions. This approach was
an iterative process whereby all high quality autosomal SNPs were
used to calculate the top 50 principal components. Once
calculated, the principal components were examined to
determine if they were tied to regions of the genome. If so, those
SNPs were excluded and the analysis repeated. The first principal
component (PC1) explained the largest proportion of variation at
22% and was used as a covariate in all analyses. A direct
comparison of the PCA with FRAPPE [46] analysis of 70 ancestry
informative markers (AIMs; [47]) resulted in a high correlation
between PC1 and the AIMs ancestry estimates, r
2=0.87. The
mean (SD) African ancestry proportion in 965 T2DM-ESRD cases
and 1,029 controls was 0.8060.11 and 0.7860.11, respectively, as
estimated by FRAPPE analysis. Other principal components were
associated with regions of the genome, representing another
unclassified source of variance. To test for association with
T2DM-ESRD, genotypic tests of association were performed on
each SNP individually using SNPGWA (www.phs.wfubmc.edu;
[48]), an analytic package which includes the capability to perform
association calculations adjusting for covariates. The primary
inference was based on the additive genetic model; with note when
there is strong evidence of a departure from additivity. The
inflation factor was calculated as the observed mean of the chi
squared statistic and compared to its theoretical expectation of 1
under the null hypothesis.
Imputation was performed for autosomes using MACH (version
1.0.16, http://www.sph.umich.edu/csg/abecasis/MaCH/) to ob-
tain missing genotypes for previously identified T2DM index
variants and to provide support for regions associated with T2DM
in the African American dataset. SNPs with minor allele frequency
$1%, call rate $95% and Hardy–Weinberg P-value $10
24 were
used for imputation. A 1:1 mixture of the HapMap II release 22
(NCBI build 36) CEU:YRI consensus haplotypes (http://math-
gen.stats.ox.ac.uk/impute/) were used as a reference panel.
Imputation was performed in two steps. For the first step, 484
unrelated African-American samples were randomly selected to
calculate recombination and error rate estimates. In the second
step, these rates were used to impute all samples across the SNPs in
the entire reference panel. Imputation results were filtered at an
rsq threshold of $0.3 and a minor allele frequency $0.05.
We examined previously identified T2DM loci for association
with T2DM in the African American GWAS dataset. For SNPs
not available on the Affymetrix 6.0 array or from direct
genotyping (n=10), genotypes were determined from imputation.
In addition to the index variant, we identified the corresponding
LD block using the HapMap phase II CEU data as defined by
Gabriel et al. [49] and implemented in Haploview. These intervals
were then extracted from the African-American GWAS and the
most significant SNP identified. These results were corrected for
the effective number of SNPs (independent SNPs) in each locus
counted using the Li and Ji method implemented in SOLAR [50].
The empirical locus-specific P-values were adjusted for multiple
comparisons by Bonferroni correction for the effective number of
SNPs (Table S1).
Replication in T2DM-ESRD cases and controls lacking
T2DM and ESRD. To account for admixture in the replication
cohort, ancestral allele proportions were estimated by comparing
allele frequencies to 70 AIMs [47] genotyped in 44 Yoruba
Nigerians and 39 European Americans. Individual ancestral
proportions were generated for each subject using FRAPPE
[46], an EM algorithm-based approach, under a two-population
model and used as covariates in all analyses. The mean (SD)
African ancestry proportion in 709 T2DM-ESRD cases and 690
controls was 0.8060.12 and 0.7660.13, respectively. Association
analysis was performed as described for the GWAS.
Validation in T2DM, non-nephropathy cases and controls
lacking T2DM and ESRD. In order to discriminate between
association with T2DM and T2DM-ESRD, meta-analysis of three
additional association analyses was performed. For the T2DM
population, individual admixture proportions were estimated by
comparing allele frequencies from 76 AIMs genotyped on the
Type 2 Diabetes GWAS in African Americans
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(controls) to frequencies reported in the HapMap CEU and YRI
populations (unrelated samples only). Individual ancestral
proportions were generated for each subject using FRAPPE [46]
under a two-population model and used as covariates in all
analyses. The mean (SD) African ancestry proportion in T2DM
cases and controls was 0.7860.11 and 0.7660.12, respectively.
Association analysis was performed as described for the GWAS.
For the IRAS and IRASFS cohorts, ancestral allele frequencies
were estimated using 70 AIMs genotyped in 44 Yoruba Nigerians
and 39 European Americans. Individual ancestral proportions
were generated for each subject using FRAPPE [46] under a two-
population model and used as covariates in all analyses. For the
IRASFS cohort, each SNP was examined for Mendelian
inconsistencies using PedCheck [51]. Genotypes inconsistent
with Mendelian inheritance were converted to missing.
Maximum likelihood estimates of allele frequencies were
computed using the largest set of unrelated African-American
individuals (n=58), and then genotypes were tested for departures
from Hardy-Weinberg proportions. For the IRAS (unrelated
individuals) and IRASFS (related individuals) cohorts, data was
analyzed using a variance component measured genotype model
[50]. To model T2DM as the outcome, a threshold model of the
variance component measured genotype model was used.
Likelihood ratio tests were computed for the tests of association
with the individual SNP, modeling the correlation structure
suggested by the familial relationships as appropriate, i.e. IRASFS.
The family data has already been examined in detail and familial
relationships corrected based on a linkage panel. P-values were
calculated from the threshold model while the odds ratios were
calculated from a logistic regression model.
Meta-Analyses. In order to perform GWAS + Replication,
Validation (T2DM, IRAS and IRASFS) and Overall (GWAS +
Replication + Validation) analyses a meta-analysis approach was
taken. Meta-analysis was performed using the weighted Z-method
implemented in METAL (www.sph.umich.edu/csg/abecasis/
metal). This approach allows P-values and direction of effect to
be combined independent of b-estimates, allowing for
incompatibility between phenotype units as in the Fisher method
[52], but with improved power and precision over Fisher’s test
[53]. The Z-statistic was derived from the sample-specific P-values
and directionality of effect which were then summed with weights
proportional to the square root of the sample size for each sub-
study.
Quantitative Trait Analysis. To test for association
between individual SNPs and quantitative measures of glucose
homeostasis in the IRAS and IRASFS cohorts, differences in trait
values by genotype were tested using the variance components
model that explicitly models the correlation among related
individuals as implemented in SOLAR (12). For statistical
testing, trait values were transformed to best approximate the
distributional assumptions of the test and to minimize
heterogeneity of the variance. The primary statistical inference
was the additive genetic model. All tests were computed after
adjustment for age, gender, BMI and admixture adjustment.
Exploration of eQTLS for T2DM loci
To identify potential T2DM-susceptibility genes we explored
association of the putative African-American T2DM loci with
transcript levels for flanking genes using gene expression profiles
from the publically available HapMap Yoruba (YRI) dataset [54].
Coupling the YRI expression dataset with genotypes from the
most associated loci we explored the association of SNPs with
flanking genes using the variance components model and
accounting for correlation among related individuals as imple-
mented in SOLAR (12).
Supporting Information
Figure S1 Quartile-Quartile plot of the genome-wide
association study results.
(DOC)
Figure S2 African-American T2DM candidate regions.
A) rs7542900 region. B) rs4659485 region. C) rs7560163 region.
D) rs2722769 region. E) rs7107217 region. 2log10 additive P-value
from the GWAS are plotted versus position (NCBI Build 36.1,
hg18). The large red diamond indicates the additive P-value from
the GWAS of the marker(s) displayed. The large blue diamond
and corresponding P-value indicates the additive P-values from
the Overall analysis of the marker(s) displayed. r
2 based on the
control samples is color-coded with respect to the most significant
SNP: red (0.8–1.0), orange (0.5–0.8), yellow (0.2–0.5) and white
(,0.2). Gene annotations were obtained from UCSC Genome
Browser (RefSeq Genes, b36). Arrows represent direction of
transcription.
(DOC)
Table S1 GWAS P-values for previously associated
T2DM loci. Loci are ordered by chromosome and position
(NCBI Build 36.1, hg18) and referenced (Ref) by the initial
publication. The African American major/minor alleles are
presented on the positive strand with the Caucasian risk allele
underlined. For each T2DM Index SNP, results from the African
American GWAS (the minor allele frequency (MAF) for the
T2DM-ESRD and control populations or combined for imputed
SNPs with the corresponding additive P-value and odds ratio (OR)
with associated 95% confidence interval (CI)) are presented with
respect to the published risk allele (underlined). In addition,
association results (additive P-value and odds ratio (OR) with
associated 95% confidence interval (CI)) from recent Caucasian
large-scale meta-analyses with associated references (Ref) are listed
for comparison. For each index SNP, the corresponding LD block
was identified using the HapMap phase II CEU data as defined by
Gabriel et al. and implemented in Haploview. These intervals were
then extracted from the African-American GWAS and the most
significant SNP listed. From the GWAS, the minor allele
frequency (MAF) for the T2DM-ESRD and control populations
are listed with the corresponding additive P-value (nominal and
corrected for the effective number of tests at the locus (number of
SNPs genotyped in the GWAS and effective number of SNPs
determined from the Li and Ji method and implemented in
SOLAR)) and odds ratio (OR) with associated 95% confidence
interval (CI) with respect to the African-American minor allele.
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Table S2 GWAS, Replication, T2DM, IRAS and IRASFS
P-values for 122 GWAS SNPs genotyped on replication
and validation samples. SNPs are ordered by chromosome
and position (NCBI Build 36.1) with the major/minor alleles
(positive strand). For each cohort, minor allele frequency (MAF)
for case and control populations are listed with the reference allele
(minor allele) and corresponding additive P-value and odds ratio
(OR) with associated 95% confidence interval (CI) with respect to
the minor allele. Note: For IRAS-FS MAFs are derived from the
overall sample including relatives. In addition, allele frequencies
has been extracted from HapMap Yoruba (YRI) and CEPH
(CEU) samples for comparison. Rows in red type represent the five
loci which are the focus of the manuscript.
(XLS)
Type 2 Diabetes GWAS in African Americans
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29202Table S3 Validation P-values for T2DM loci across the
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and corresponding gene (underlined) or nearest annotated gene.
For the T2DM, IRAS and IRASFS analyses, the minor allele
frequency (MAF) for T2DM and control populations are listed
with the corresponding additive P-value. Note: For IRASFS MAFs
are derived from the overall sample including relatives. For the
Validation meta-analysis the additive P-value and odds ratio (OR)
with associated 95% confidence interval (CI) are presented with
respect to the minor allele.
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Table S4 Association results for African-American
T2DM loci in the Diabetes Genetics Replication and
Meta-analysis (DIAGRAM) Consortium. SNPs are ordered
by chromosome and position (NCBI Build 36.1, hg18) and the
nearest annotated gene is listed. For each SNP the major/minor
alleles identified in the Overall African-American meta-analysis
are indexed on the forward strand. Results from the association
analysis in the Overall African-American cohort and DIAGRAM
Consortium include the allele frequency (AF), odds ratio (OR) with
associated 95% confidence interval (CI) and P-value with respect to
the minor allele identified in the African-American population.
SNP rs7560163 did not pass quality control filters in the
DIAGRAM Consortium and was not included in analysis.
(DOC)
Table S5 Quantitative trait meta-analysis for African-
American T2DM loci across the genome. SNPs are ordered
by chromosome and position (NCBI Build 36.1, hg18) with the
major/minor alleles (positive strand) and the nearest annotated
gene is listed. For the IRAS and IRASFS samples, the b coefficient
with respect to the minor allele is listed with the corresponding
additive P-value. For the meta-analysis, the z-statistics is listed with
the corresponding additive P-value.
(DOC)
Table S6 Association results for African-American
T2DM loci in the Meta-Analyses of Glucose and
Insulin-related traits Consortium (MAGIC). SNPs are
ordered by chromosome and position (NCBI Build 36.1, hg18)
with the alleles on the positive strand (African American risk alleles
are underlined) and the nearest annotated gene is listed. For each
SNP and trait combination, the effect size and standard error are
listed with the corresponding P-value.
(DOC)
Table S7 Gender stratified association analysis with
T2DM. SNPs are ordered by chromosome and position (NCBI
Build 36.1, hg18) with the major/minor alleles (positive strand)
and corresponding gene (underlined) or nearest annotated genes
(+/2500 kb). For males and females, the additive P-value and
odds ratio (OR) with associated 95% confidence interval (CI) with
respect to the minor allele and heterozygosity P-value are listed.
(DOC)
Table S8 Power Calculations. Table S8a. Genome-wide
association study power analysis for causal variant in complete and
incomplete linkage disequilibrium with a typed variant given
minor allele frequency (p) in 965 cases and 1029 controls. Table
S8b. Replication power analysis for causal variant in complete and
incomplete linkage disequilibrium with a typed variant given
minor allele frequency (p) in 709 cases and 690 controls. Table
S8c. GWAS + Replication sample power analysis for causal
variant in complete and incomplete linkage disequilibrium with a
typed variant given minor allele frequency (p) in 1674 cases and
1719 controls. Table S8d. T2DM power analysis for causal variant
in complete and incomplete linkage disequilibrium with a typed
variant given minor allele frequency (p) in 1246 cases and 927
controls. Table S8e. IRAS power analysis for causal variant in
complete and incomplete linkage disequilibrium with a typed
variant given minor allele frequency (p) in 115 cases and 164
controls. Table S8f. IRASFS power analysis for causal variant in
complete and incomplete linkage disequilibrium with a typed
variant given minor allele frequency (p) in 97 cases and 507
controls. Table S8g. Validation meta-analysis power analysis for
causal variant in complete and incomplete linkage disequilibrium
with a typed variant given minor allele frequency (p) in 1458 cases
and 1598 controls. Table S8h. Overall power analysis for causal
variant in complete and incomplete linkage disequilibrium with a
typed variant given minor allele frequency (p) in 3132 cases and
3317 controls.
(DOC)
Table S9 IRAS and IRASFS power analysis to detect a
causal variant with the effect size observed in the T2DM
cohort.
(DOC)
Table S10 P-values for putative ESRD loci across the
genome. SNPs selected from the GWAS (P,0.001) and
associated in the Replication cohort (P,0.05 and directionally
consistent) but which were not associated in the Validation cohort
(P.0.05) and could represent putative ESRD loci. SNPs are
ordered by chromosome and position (NCBI Build 36.1) with the
major/minor alleles (positive strand) and corresponding gene
(underlined) or nearest annotated gene. For each phase of the
study, GWAS + Replication, Validation and Overall analyses, the
additive P-value and odds ratio (OR) with associated 95%
confidence interval (CI) with respect to the minor allele is listed.
(DOC)
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